Provided by Tiger Trade Technology Pte. Ltd.

Taysha Gene Therapies, Inc.

4.61
+0.20004.54%
Post-market: 4.36-0.2500-5.42%19:55 EST
Volume:2.64M
Turnover:12.05M
Market Cap:1.26B
PE:-13.72
High:4.70
Open:4.60
Low:4.44
Close:4.41
52wk High:6.02
52wk Low:1.05
Shares:273.92M
Float Shares:184.00M
Volume Ratio:1.14
T/O Rate:1.43%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.3359
EPS(LYR):-0.3570
ROE:-64.93%
ROA:-25.70%
PB:5.77
PE(LYR):-12.91

Loading ...

Taysha Gene Therapies Grants 349,000 RSUs to New Employees

Reuters
·
Yesterday

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Yesterday

Aehr, Fastenal, Regions, Abeona, Taysha: Insider Firestorm

TIPRANKS
·
Jan 31

Why Taysha Gene Therapies (TSHA) Is Down 6.3% After Rett Trial Progress And Insider Stock Sales - And What's Next

Simply Wall St.
·
Jan 29

Top Taysha Gene Therapies Insiders Make Major Moves With Their Own Shares

TIPRANKS
·
Jan 28

Taysha Gene Therapies Is Maintained at Buy by Chardan Capital

Dow Jones
·
Jan 07

Taysha Gene Therapies Doses First Patient in Pivotal Rett Syndrome Gene Therapy Trial

Reuters
·
Jan 06

Taysha Gene Therapies Announces Progress Across Tsha-102 Pivotal Gene Therapy Program in Rett Syndrome

THOMSON REUTERS
·
Jan 06

Taysha Gene Therapies : Longer-Term Safety & Efficacy Data Update From Part a of Reveal Phase 1/2 Trials Expected in H1 2026

THOMSON REUTERS
·
Jan 06

Taysha Gene Therapies: Completion of Dosing in Reveal Pivotal Trial & Aspire Trial Expected in Q2 2026

THOMSON REUTERS
·
Jan 06

Taysha Gene Therapies Is Maintained at Overweight by Wells Fargo

Dow Jones
·
Jan 06

Taysha Gene Therapies (TSHA): Revisiting Valuation After TSHA-102 Breakthrough Designation and Trial Milestones

Simply Wall St.
·
Dec 24, 2025

Should Rett Breakthrough Status and Pivotal Trial Plan Require Action From Taysha Gene Therapies (TSHA) Investors?

Simply Wall St.
·
Dec 22, 2025

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Dec 06, 2025

Cantor Fitzgerald Adjusts Price Target on Taysha Gene Therapies to $19 From $13, Maintains Overweight Rating

MT Newswires Live
·
Nov 21, 2025

Taysha price target raised to $19 from $13 at Cantor Fitzgerald

TIPRANKS
·
Nov 21, 2025

Citizens JMP healthcare analysts hold an analyst/industry conference

TIPRANKS
·
Nov 19, 2025

Taysha Gene Therapies Unveils Advances in One-Time Gene Therapy for Rett Syndrome

Reuters
·
Nov 13, 2025

Stock Track | Taysha Gene Therapies Soars 6.56% on Analyst Upgrades and Positive Q3 Results

Stock Track
·
Nov 05, 2025

Stock Track | Taysha Gene Therapies Soars 5.39% Pre-market on Positive Analyst Ratings and Q3 Results

Stock Track
·
Nov 05, 2025